CCS
BEAT

Crosspoint Capital Strategies’s BioTelemetry, Inc. BEAT Stock Holding History

Crosspoint Capital Strategies’s Portfolio BEAT Stock Details BEAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.24M Buy
+19,785
New +$1.36M 2.24% 31

Other funds holding BEAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Crosspoint Capital Strategies's BEAT Position: Q1 2019 in Review

Crosspoint Capital Strategies opened a new position in BioTelemetry, Inc. (BEAT) in Q1 2019: 19,785 shares worth $1.24M. The stake represents 2.24% of the portfolio and ranks #31 among its holdings.

311 funds tracked by Wall St. Rank hold BEAT as of Q1 2019.

  • Crosspoint Capital Strategies held 19,785 shares of BioTelemetry, Inc. worth $1.24M as of Q1 2019.
  • BioTelemetry, Inc. was a new Crosspoint Capital Strategies position in Q1 2019.
  • BioTelemetry, Inc. made up 2.24% of Crosspoint Capital Strategies's portfolio in Q1 2019, its #31 holding.
  • 311 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2019.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2019, filed 13 May 2019.